Aspergillosis Market

DelveInsight’s Aspergillosis market report offers comprehensive coverage of the current treatment practices, pipeline therapies, and market share of the individual drug, current and forecasted Aspergillosis market size from 2018 to 2030 in the 7MM.

Key Takeaways from the Aspergillosis Market Report

• As per DelveInsight estimates, three Major Subtypes (ABPA, IA, and CPA) prevalent population was found to be 555,840 in the US in 2020.
• The diagnosed and treated cases of ABPA were highest in the US, followed by IA and CPA in 2020.
• Among the EU5 countries, the UK had the highest diagnosed and treated Aspergillosis cases in 2020.
• Leading companies in the Aspergillosis market include F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide, Sanofi, and others.
• Key Aspergillosis therapies in the pipeline include Olorofim, Pulmazole, Voriconazole dry-powder inhalation (TFF-VORI), Ibrexafungerp, PC945, Dupilumab, and others. 

Request for Aspergillosis market report sample to understand more about the emerging drug landscape @ Aspergillosis Market Outlook

Aspergillosis Overview

Aspergillosis is an infection or allergic reaction caused by the fungus Aspergillus, common in the environment. The most common types of aspergillosis are chronic pulmonary aspergillosis (CPA), invasive aspergillosis (IA), and allergic bronchopulmonary aspergillosis (ABPA).

Aspergillosis Epidemiology Segmentation

The Aspergillosis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Aspergillosis Prevalent Cases 
• Aspergillosis Diagnosed and Treated Cases

Aspergillosis Treatment Landscape

Antifungal medications, such as Azoles, Echinocandins, and Amphotericin B, are currently the most commonly used treatment modality for Aspergillosis. Several triazoles, including voriconazole and isavuconazole, are also used  to treat invasive aspergillosis.

Aspergillosis Market Outlook

Several approved therapies are driving the current Aspergillosis therapeutic landscape in the United States. The launch of the most anticipated therapies such as Ibrexafungerp, PC945, Dupilumab, and others, which are expected to show changes in the current Aspergillosis market, is the primary reason for the market upsurge.

Discover more about the future market share of the drugs @ Aspergillosis Market Share

Aspergillosis Pipeline Therapies and Key Companies 

• Olorofim: F2G 
• Pulmazole (PUR1900): Pulmatrix
• Voriconazole dry-powder inhalation (TFF-VORI): TFF Pharmaceuticals
• Ibrexafungerp: Scynexis
• PC945: Pulmocide
• Dupilumab: Sanofi

Table of Contents 

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Invasive Aspergillosis Market

DelveInsight’s “Invasive Aspergillosis- Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Invasive Aspergillosis, historical and forecasted epidemiology as well as the Invasive Aspergillosis market trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/